To Cisco and Buck, I've also noticed the recent insider selling. 'But from reviewing the 10K, Dec 31, 1996, it would seem that someone, or a group, seems to hold 8 million shares. This may have changed, but it seems that they may hold a majority of the shares.
Also, I had read the Ob/Gyn article when it first came out and at that time, it was not as good as I would have wanted it, but it was not the only study that was submitted to the FDA. Subsequently, the additional studies seem to showing that the thinprep is better than the aggregate studies indicated. I think it would be hard for cytyc to buy the whole world off.
I have been starting to look at acumed and so far, I'm not sure how it fits in when compared to it's competators. I know I do not like Leica, so I have to balance out my initial impression of that company. The decrease in reportining time is not anything exclusive to acmi. The important thing is whether the instrument itself can fit in with the thinprep. I think cytyc is also coming out with a similar instrument to acmi. Also the initial study by npth with cytyc looked promising, but I will say that all of the automated slide reader companies seem to be vague with releasing the complete data that I w2ould like to see to evaluated what is going on.
Can anyone, in a few paragraphs give concrete numbers that show why acmi is moving forward. Not the sayso of company officials. I am interested. With the info I have read so far here, I would not but this stock. |
